ProSiebenSat.1 Group increases full-year outlook based on strong revenue and adjusted EBITDA growth in the second quarter of 2021
|
DGAP-Ad-hoc: ProSiebenSat.1 Media SE / Key word(s): Quarterly / Interim Statement/Forecast
Unterföhring, July 19, 2021. ProSiebenSat.1 Group revenues increased considerably by 47% to around EUR 1,045 million (previous year: EUR 709 million) in the second quarter of 2021 on the basis of preliminary and unaudited figures. Adjusted EBITDA also developed very positively on this basis and grew more than sevenfold to around EUR 165 million (previous year: EUR 23 million). This was especially driven by the dynamic increase of the Group's advertising revenues in the region of Germany, Austria and Switzerland which increased by 56% compared to the previous-year quarter. The Group thus recorded a very strong recovery compared to the COVID-19 impacted previous-year quarter.
Following this substantial and profitable growth, the Group also again increases its outlook for financial year 2021 which most recently had been adapted on May 12, 2021 on the occasion of the Q1 2021 Quarterly Statement: In total, the Group is now targeting for full-year 2021 - without further portfolio changes - revenues of EUR 4.400 billion (previously: EUR 4.250 billion) as the lower end and revenues of EUR 4.500 billion (previously: EUR 4.450 billion) as the upper end of the target range (previous-year figure adjusted for currency and portfolio effects: EUR 4.055 billion(1)). In financial year 2021, Group revenue growth would thus be in a range between 9% and 11% compared to the previous year (previously: 5% to 10%). Based on these revenue assumptions, for the full-year of 2021 ProSiebenSat.1 now anticipates a Group adjusted EBITDA - without further portfolio changes - of around EUR 820 million with a variance of plus/minus EUR 20 million (previously: target range of EUR 750 million to EUR 800 million; previous-year figure adjusted for currency and portfolio effects: EUR 708 million(2)). This corresponds for the mid-point to a year-on-year increase of 16%. (1) Based on revenues in financial year 2020 translated at the exchange rates used for planning purposes in financial year 2021 (EUR/USD exchange rate of around USD 1.22) less revenues of the companies deconsolidated in 2020 - WindStar Medical at EUR 114 million and myLoc at EUR 10 million - plus pro forma revenues for The Meet Group between January and August 2020 of EUR 173 million, also translated at the exchange rate used for planning purposes in financial year 2021 (EUR/USD exchange rate of around USD 1.22). (2) Based on adjusted EBITDA in financial year 2020 translated at the exchange rates used for planning purposes in financial year 2021 (EUR/USD exchange rate of around USD 1.22) less adjusted EBITDA of the companies deconsolidated in 2020 - WindStar Medical at EUR 23 million and myLoc at EUR 3 million - plus the pro forma adjusted EBITDA contributions for The Meet Group between January and August 2020 of EUR 33 million, also translated at the exchange rate used for planning purposes in financial year 2021 (EUR/USD exchange rate of around USD 1.22). Contact: Stefanie Rupp-Menedetter Head of Group Communications & Events ProSiebenSat.1 Media SE Medienallee 7 · D-85774 Unterföhring Tel. +49 89 950 725 98 Mobil +49 17 283 527 03 Stefanie.Rupp@prosiebensat1.com
19-Jul-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | ProSiebenSat.1 Media SE |
| Medienallee 7 | |
| 85774 Unterföhring | |
| Germany | |
| Phone: | +49 (0)89 9507-1463 |
| Fax: | +49 (0)89 9507-91463 |
| E-mail: | Dirk.Voigtlaender@ProSiebenSat1.com |
| Internet: | www.prosiebensat1.com |
| ISIN: | DE000PSM7770 |
| WKN: | 777117 |
| Indices: | MDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Luxembourg Stock Exchange |
| EQS News ID: | 1220074 |
| End of Announcement | DGAP News Service |
|
|
1220074 19-Jul-2021 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.